Phase 1 to 4
Phase 1 to 4 exists to assist companies in integrating all existing knowledge about their compound or device, the condition it seeks to treat as well as state-of-the-art clinical research technology, regulatory and commercial environment. This integration serves as a basis for optimal planning and execution of rapid clinical development and subsequent medical and commercial success.

Phase 1 to 4 is managed by Poul Strange MD, PHD, who following academia has 15 years of pharmaceutical industry experience in positions ranging from drug discovery in the laboratories through pharmacology, clinical pharmacology, clinical development, and medical affairs, as well as three years of experience as an independent consultant to the biotech, device and pharmaceutical industries. Therapeutic area experience spans metabolism, cardiovascular disease, thrombosis, immunology supplemented with some oncology and neuroscience. Regulatory experience covers small molecules, biologics and devices.